Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
AmyloiDia Sweden AB is active in the Biotechnology & Pharmaceuticals technology area. The company currently manages 1 pending office action. This matter is assigned to 1 distinct examiner and is located within a distinct art unit. This structure indicates a focused prosecution strategy where all current activity is directed through the point of contact at the patent office. Such a concentrated approach often characterizes portfolios with specific technical goals.
The busiest examiner for the portfolio is KIRWIN, STEFANIE JOHANNA. This examiner is responsible for the busiest examiner pending office action. Since this workload represents the total pending volume for the company, the prosecution's progress is tied to the findings of this specific individual. For a practitioner, this concentration allows for a streamlined response process. However, it also means the portfolio lacks the examiner diversity found in larger sets of filings. The resolution of this pending matter will be a factor in the company's near-term intellectual property position.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIRWIN, STEFANIE JOHANNA | 1 | 15.6% | +29.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17044199 | METHOD FOR THE DIAGNOSIS OF AMYLOID-ASSOCIATED DISEASES | KIRWIN, STEFANIE JOHANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17044199 | METHOD FOR THE DIAGNOSIS OF AMYLOID-ASSOCIATED DISEASES | KIRWIN, STEFANIE JOHANNA | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17044199 | METHOD FOR THE DIAGNOSIS OF AMYLOID-ASSOCIATED DISEASES | KIRWIN, STEFANIE JOHANNA | 1677 | §103 | Non-Final OA | — | Pending | Sep 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmyloiDia Sweden AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Stefanie Johanna Kirwin has the most, with 1 of AmyloiDia Sweden AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
